← All trials
NCT03292783
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2017
- Primary completion
- Sep 16, 2019
- Completion date
- Dec 27, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 39
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National OncoVentureLead sponsor
- ABL Bio Inc.Collaborator
- National OncoVentureStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.